Should the cloning of human embryos to aid in the development of medical therapies be permitted?

For two leading stem cell researchers, Dr. Catherine Verfaillie and Dr. Austin Smith, the answer is an emphatic ‘yes.’

Verfaillie, director of the University of Minnesota Stem Cell Institute, and Smith, director of the Centre for Genome Research at the University of Edinburgh in Scotland, addressed this and other controversial subjects during a recent speech at the University of Minnesota.

Smith acknowledged that cloning is a hot-button issue, but called the furor ‘more emotional than logical,’ noting there is often a failure to distinguish between therapeutic and reproductive cloning.

While he called the latter ‘irresponsible,’ many countries in Europe are moving toward the production of embryonic stem cells for therapeutic purposes.

The U.S. House of Representatives has voted to ban both types of cloning.

President Bush has indicated he would sign the proposal should it reach his desk.

‘Scientists have always been accused of playing God,’ Smith said, adding that the job of science is to use the natural world to improve people’s lives.

‘We don’t want to clone Saddam Hussein. We want to help sick people.’

Recent discoveries in the area of stem cell research have brought much attention to the U of M.

Verfaillie and her colleagues announced last year that adult stem cells have demonstrated the potential to differentiate into other types of cells.

‘Your discovery will fundamentally change the way people think about this subject,’ Smith said.

‘Adult stem cells are not as restrictive as we thought.’

The goal with both embryonic and adult cells is to purify or ‘coach’ them into becoming other types of cells.

Neural cells would be ideal, said Smith. ‘We are nowhere near where we need to be’ for clinical application, he said. ‘We need purification technology’ to target the cells for development.

‘The challenges are not insignificant, but they are approachable.’

Ironically, little attention has been paid to another source of stem cells that faces no limits or prohibitions: aborted fetuses between 8-12 weeks gestation.

Dr. Carol Tauer, senior scholar at the Minnesota Center for Health Care Ethics, said virtually no public debate has occurred in this area.

‘Much of the energy has been focused on the creation and destruction of embryos for research purposes,’ she said.

Last August, President Bush limited the use of federal funds for embryonic stem cell research to the 64 lines of cells that have already been developed.

Pro-life organizations and politicians have seized on Verfaillie’s adult stem cell discovery to say there is no need to focus on embryonic research.

Both Verfaillie and Smith said it was too early to limit any efforts in this budding field.

Both agree that embryonic cells must be compared to adult stem cells and studied.

‘It is too early to cry victory for one type of cell,’ Verfaillie said.

She is now recruiting two embryonic stem cell researchers to the Stem Cell Institute at the U of M.

What does this mean for the disability community? Stem cell research holds tremendous promise to check the progress of and potentially reverse the effects of many diseases and chronic conditions. The ethical implications of both the methods and application of the research have been called as boundless as the potential for clinical improvements.

Among the first to benefit from the research will be those with Parkinson’s disease, said Smith, who predicts we are five to 10 years away from clinical trials. Since the condition stems from a specific gene abnormality, its therapeutic solution is more easily identifiable. Diabetes, on the other hand, is more complicated, resulting in multiple challenges to the body’s immunological system. Treatments for ALS will be similarly difficult. Other “single gene” diseases, such as hemophilia, will also see benefits early on, said Smith.

While neither directly addressed the disability community in their comments, Smith was asked if stem cell research could lead us to a therapeutic fountain of youth. “People will not live forever or stop aging as a result of my efforts,” Smith said, “but quality of life will be improved…not just for the affected individual, but for the family and other supporters as well.”


John Tschida is the Senior Director of Public Affairs and Research at Courage Center.

Announcement about changes to Medical Assistance, highlighting that those with disabilities are exempt from new work requirements.
Thank you message highlighting sponsors ARRM, Sanford Health, and Winthrop & Weinstine for supporting accessibility and journalism.